



# CELLS TO SURGERY 2019

2nd ROTTERDAM SKIN CANCER CONGRESS

## 6, 7, 8 FEBRUARY

### WEDNESDAY 6th 17.00 – 20.00

#### Welcome to Cells to Surgery

Tamar Nijsten

#### Triple therapy in melanoma: more is better

James Larkin - Royal Marsden Hospital, London

#### Gut microbiome and response to anti-PD-1

Jennifer Wargo - MD Anderson Cancer Center, Houston

#### Staging issues of cutaneous squamous cell carcinoma

Chrysalynne Schmults - Brigham and Women's hospital, Boston

### THURSDAY 7th 09.00 – 18.10

#### Controverses in melanoma pathology

Antien Mooyaart - Erasmus MC, Rotterdam

#### Update basic immunology in melanoma

TBA

#### Adjuvant immunotherapy in melanoma

Carolien Robert - Gustave-Roussy Institute, Paris

#### Impact of 8th AJCC on melanoma outcomes

Max Madu - NKI-AvL, Amsterdam

#### Micrographic Mohs surgery for CSCC

Renate van den Bos - Erasmus MC, Rotterdam

#### Sentinel Node procedure for NMSC in head and neck region

Michiel van den Brekel - NKI-AvL, Amsterdam

#### Isolated limb perfusion in CSCC

Eva Huis in 't Veld - NKI-AvL, Amsterdam

#### Anti-PD1 treatment in advanced CSCC

Dirk Schadendorf - University Hospital Essen

#### How to best deal with drug pricing and drug costs

Carin den Uyl-den Groot - Erasmus University, Rotterdam

#### Prognosis of Merkel cell carcinoma

Linde van Veenendaal - NKI-AvL, Amsterdam

#### Avelumab for Merkel cell carcinoma

Hilde Jalving - UMCG, Groningen

#### Pro Contra debate

#### Adjuvante TT vs. adjuvante IO voor BRAF+ stadium III melanoom

Astrid van der Veldt - Erasmus MC, Rotterdam & Karijn Suijkerbuijk - UMCU, Utrecht

#### Melanoma treatment in immunocompromised patients

TBA

#### Role of TVEC in melanoma treatment

Dirk Grünhagen - Erasmus MC, Rotterdam

#### Pro Contra debate

#### Locoregional therapy vs. systemic therapy for in transit metastasis

Christian Blank & Alexander van Akkooi - NKI-AvL, Amsterdam

#### Treatment of melanoma brain mets

Martin van den Bent - Erasmus MC, Rotterdam

#### Organisation of melanoma care (in The Netherlands)

TBA

### FRIDAY 8th 08.45 – 15.20

#### Melanoma mortality: the Breslow paradox

Loes Hollestein - Erasmus MC, Rotterdam

#### What to do with stage II melanoma?

Lex Eggermont - Gustave-Roussy Institute, Paris

#### Risk of melanoma in lentigo maligna

Judith Zoutendijk - Erasmus MC, Rotterdam

#### Skin cancer mortality in transplant recipients

TBA

#### Genetic Influence on Skin Cancer and Nevus Count

Veronique Bataille - King's College London, London

#### Skin cancer costs in The Netherlands

Eline Noels - Erasmus MC, Rotterdam

#### Comparative RCT of topical AK therapies: 1 year results

Maud Jansen - MUMC, Maastricht

#### Basal cell carcinoma, genetics and clinical implications

Klara Mosterd - MUMC, Maastricht

#### Prognostic factors of CSCC progression: recent insights from UK

Tamar Nijsten - Erasmus MC, Rotterdam

#### Views and opinions of patients and providers on skin cancer care

Sven van Egmond - Erasmus MC, Rotterdam

#### The expansion of Mohs micrographic surgery in The Netherlands

Marcus Muche - Mohs klinieken, Hoorn

#### Tips & tricks of complex reconstruction in head and neck region

Koen Ingels - Radboud UMC, Nijmegen

#### How to deal with advanced keratinocytic cancers?

Alexander Stratigos - A. Sygros Hospital, Athens

Organized by:



For more information and registration visit the website: [www.cellstosurgery.com](http://www.cellstosurgery.com)

PARTNERS GALDERMA MEDA NOVARTIS